Updated 2018 - 2020 Review of Patient-Reported Outcomes in Orphan Drug Labels Approved by the US Food and Drug Administration
Author(s)
Brown Hajdukova E1, Girardi A2, Rzepa E3, Scippa K4, Rudell K5
1Parexel International, Prague, Czech Republic, 2Parexel International, London, LON, UK, 3Parexel International, Uxbridge, UK, 4Parexel International, Billerica, MA, USA, 5Parexel International, Chittering, CAM, UK
Background: Despite increasing recognition of the need to assess treatment benefit from the patient’s perspective, the extent of patient-reported outcome (PRO) data included in labeling for rare disease treatment is often unknown. Objective: The objective of this review was to extend on Hong’s at al. review of PRO-based labeling granted by the US Food and Drug Administration (FDA) for orphan drugs between 2002 – 2017 with an aim to provide a more current review of PRO labelling trends. Methods: Products included in this review were all new molecular entities (NMEs) and biologic license applications (BLAs) with orphan designations approved by the FDA from 2018 through 2020. For identified products, package inserts were reviewed to determine the number and type of PRO claim(s) granted, endpoint status, and PRO measure named. Results: A total of 87 NMEs and BLAs with orphan designations were approved between 2018 and 2020 in comparison to 156 between 2002- 2017. Of these 87 products, 15 products (13.04%) had PRO-based labeling and 5 were approved for paediatric population in comparison to only 13 products (8.3%) and 2 paediatric PRO-based labels between 2002 -2017. Conclusions: In FDA-approved labeling for orphan therapies, PRO measures used as primary and secondary endpoints increased in 2018-2020. Despite this positive trend, more in-depth knowledge of challenges relating to PRO measure implementation is needed to ensure that treatments capture perspectives of patients with rare diseases particularly in the paediatric population. Keywords: labeling, orphan drugs, patient-reported outcomes, rare diseases Reference: Hong, Y. D., Villalonga-Olives, E., & Perfetto, E. M. (2019). Patient-reported outcomes in orphan drug labels approved by the US food and drug administration. Value in Health, 22(8), 925-930.
Conference/Value in Health Info
2021-11, ISPOR Europe 2021, Copenhagen, Denmark
Value in Health, Volume 24, Issue 12, S2 (December 2021)
Code
POSB345
Topic
Clinical Outcomes, Methodological & Statistical Research, Patient-Centered Research
Topic Subcategory
Clinical Outcomes Assessment, Clinician Reported Outcomes, Instrument Development, Validation, & Translation, PRO & Related Methods
Disease
Rare and Orphan Diseases